Cristina Larkin
Equibles does not estimate personal net worth.
About Cristina Larkin
Cristina Larkin was last confirmed as COO at Spero Therapeutics, Inc. (SPRO) in a filing dated July 6, 2021. The proxy statement of Spero Therapeutics, Inc. reports total compensation of $1,903,930 for Cristina Larkin in fiscal 2021, including a base salary of $460,406. Disclosed compensation is on record for 2 fiscal years. Cristina Larkin has spoken on 8 earnings calls across 1 company, most recently for Spero Therapeutics, Inc. on March 31, 2022. The companies whose calls Cristina Larkin spoke on are classified in the Healthcare sector.
Cristina Larkin on recent calls
“Thank you so much, David, and it's a pleasure to be with you this evening to discuss the progress of tebipenem HBr. Our preparation for launch is focused on building a best-in-class commercial organization and creating a launch readiness plan that we believe will be a transformative treatment for cUTI.”
“As we move closer to tebipenem HBr's potential commercialization, we continue to focus on being launch-ready, including building out our launch team. As Ankit mentioned, we recently hired David Musselman as SVP of Sales and Market Access.”
“As we move closer to tebipenem HBr's potential approval, the work that we have done continues to support that this is a specialty driven launch that will be focused on urologists and IVs and that the strategy will allow us to still capture a significant portion of the approximately 2 million cUTI patients in the U.S.…”
“Our commercial market access and medical affairs teams have been working hard to prepare for our anticipated launch.”
“I am happy to detail some of the great work our commercial, market access, and medical affairs teams are doing to prepare for the tebipenem HBr, much-anticipated launch.”
Affiliation history
-
Start not stated–2021-07-06
Last confirmed by a filing; no departure on record
Company network
Executive compensation
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2021 | Spero Therapeutics, Inc. (SPRO) | Former Chief Operating Officer | $460,406 | $1,903,930 |
| 2020 | Spero Therapeutics, Inc. (SPRO) | Former Chief Operating Officer | $404,052 | $991,962 |